Australias medicines regulator has issued warnings for several type 2 diabetes and obesity-related treatments including Ozempic and Mounjaro over the potential to cause a rare but severe eye disorder that could lead to blindness
However, not all agents in the class are equivalent
Clinical research hints at a nuanced picture: interestingly, one trial with a GLP-1 analog (ROSE-010) noted that low doses actually accelerated colonic transit at 48 hours, possibly helping constipation, while higher doses mainly delayed stomach empty
For an easy-to-measure concentration of 10mg/mL, you would use 10mL of bacteriostatic water
GLP-1 receptor agonist inhibited proinflammatory monocyte chemoattractant protein-1 secretion from human atherosclerotic plaque samples and monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor- (TNF-), and interleukin (IL)-1 secretion from human macrophages after ex vivo treatment
La tirzepatida, un agonista dual que acta sobre los receptores de GLP-1 y GIP, tambin est aprobada para diabetes tipo 2 y obesidad en EE.UU